AIMEDICS – CEO Interview

AIMEDICS has developed the HypoMon which is the world’s first non-invasive night time low blood glucose management system. More than 11 million diabetic insulin users in the developed world suffer from bouts of dangerously low blood glucose several nights per month. Independent USA market research indicates that the HypoMon is a unique product addressing a recognised unmet need with a market opportunity exceeding $2 billion pa.